Gremubamab, previously known as this molecule, represents a novel therapeutic strategy targeting the biomarker in hematological malignancies . The therapeutic functions as an antibody – specifically, a humanized antibody designed to engage the body's defenses to eliminate BCMA-expressing cells . Preliminary clinical studies suggest noteworthy eff